Search company, investor...

Founded Year



Acquired | Acquired

Total Raised




About LineaGen Research

Lineagen's mission is to accelerate and enhance the diagnostic evaluation of medical conditions so that the best possible outcomes can be achieved for patients and their families. The company's first commercial offering, FirstStepDx PLUS, provides physicians with a fully integrated genetic testing, counseling, and developmental screening service to aid in the diagnostic evaluation of individuals with ASD or other forms of developmental delay. In addition to its deep commitment to ASD and developmental delay, the company has ongoing scientific programs in the areas of multiple sclerosis (MS) and chronic obstructive pulmonary disease (COPD). On August 24th, 2020, LineaGen Research was acquired by Bionano Genomics.6M.

Headquarters Location

2677 E Parleys Way

Salt Lake City, Utah, 84109,

United States




Expert Collections containing LineaGen Research

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

LineaGen Research is included in 2 Expert Collections, including Digital Health.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.


Mental Health Tech

742 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

LineaGen Research Patents

LineaGen Research has filed 21 patents.

The 3 most popular patent topics include:

  • autism
  • psychiatric diagnosis
  • genetics
patents chart

Application Date

Grant Date


Related Topics




Respiratory therapy, Lung disorders, Muscarinic antagonists, Respiratory diseases, Respiratory physiology


Application Date


Grant Date



Related Topics

Respiratory therapy, Lung disorders, Muscarinic antagonists, Respiratory diseases, Respiratory physiology



Latest LineaGen Research News

09:00 EDT MARAbio Systems, Inc. Appoints Dr. Michael Paul to Serve as Company's Chief Executive Officer

Apr 17, 2023

News provided by Share this article Share this article Proven life-sciences executive to lead groundbreaking precision medicine biotechnology company's work on Maternal Autoantibody Related Autism (MARA) SALT LAKE CITY, April 17, 2023 /PRNewswire/ -- MARAbio Systems (MARAbio), a precision medicine biotechnology company, has appointed Dr. Michael Paul to serve as the company's CEO. Dr. Paul has more than 25 years of life-sciences industry experience, including leading a number of organizations from formation to strategic exit. MARAbio's technology enables the earliest detection for risk of developing a specific subtype of autism through a simple blood test in the mother, either prior to pregnancy or after the child is born. Dr. Paul succeeds Dr. James Woody, who will continue to serve as Vice Chairman of the Board of Directors. The company has exclusive rights to key discoveries made by Founder Dr. Judy Van de Water at the UC Davis MIND Institute that forms the biological basis of Maternal Autoantibody Related Autism (MARA). MARA is an immune system-mediated subtype of autism that is currently estimated to represent approximately 20% of overall autism cases. "MARAbio's vision is a world in which the most severe effects of autism are treatable, and our entire team is energized to have Michael lead us forward," said Dr. Van de Water. "Our mission is to detect the MARA subtype that has been shown to be associated with more severe forms of autism and in some instances ensure that MARA does not occur, and Michael's appointment as CEO is a critical inflection point for us," added Dr. Van de Water. Knowing if a child has the MARA subtype of autism may help behavioral therapists tailor their intervention approaches for better outcomes. Additional indications are in development, including pre-pregnancy testing (which is particularly useful for women who are at high risk for having an autistic child), and potential therapeutics to reduce the likelihood of a child having MARA. MARAbio does not offer the test during pregnancy. "I am honored to lead this pioneering biotechnology company forward, and excited to continue working closely with Dr. Van de Water and Dr. Woody," said Dr. Paul. MARAbio's ultimate aim is to develop interventions so that families and their physicians have options to detect and limit the incidence of this subtype of autism. Combined with the potential therapeutic approaches that could block the MARA autoantibodies and prevent this subtype of autism, MARAbio is the only company applying the promise of precision medicine to autism. Dr. Van de Water's discoveries provide MARAbio with 3-fold competitive differentiation      1. Autism risk assessment test in the mother: of an autistic child and who is contemplating a subsequent pregnancy, and/or of a child who is at a high likelihood of an autism diagnosis (pre-symptomatic), thereby enabling interventions such as earlier intensive behavioral therapy. 2. Proprietary therapeutic antibody interventions: targeted against the MARA-specific autoantibodies to prevent the MARA subtype of autism. 3. Companion diagnostic test: Professional biography of Dr. Michael Paul Dr. Paul is Chief Executive Officer for MARAbio. Prior to joining MARAbio, Dr. Paul co-founded Lineagen, Inc., and served as its President, CEO, and Director from its 2006 inception to its strategic acquisition in 2020. At Lineagen, Dr. Paul built a team of over 125 employees focused on providing clinical testing services for individuals with autism and other disorders of childhood development and clinical counseling for their families. Dr. Paul is recognized as one of Utah's leading venture entrepreneurs, having been appointed to the Steering Committee for the Utah Technology Industry Commission by former Governor Michael O. Leavitt, serving as Vice Chairman for the Utah Technology Council, and as a finalist for E&Y's 2018 "Entrepreneur of the Year" in Healthcare award. In addition, MountainWest Capital Network named Lineagen as a "Utah 100 Winners" for being one of the state's fastest growing companies. Prior to founding Lineagen, Dr. Paul was Vice President of Business Development for Huntsman Biotechnology Corporate, and Director of Strategic Development at NPS Pharmaceuticals. Dr. Paul has also worked at the University of Utah Technology Transfer Office, where he marketed university inventions to the pharmaceutical and biotechnology industries. He is a licensed patent agent of the United States Patent & Trademark Office. He earned his B.A. from Colby College and his Ph.D. in Molecular Biology and Biochemistry from the University of Utah. About MARAbio MARAbio systems, Inc. is a precision medicine biotechnology company that has developed a blood test in women to identify the presence of a distinct cluster of antibodies that lead to Maternal Autoantibody Related Autism (MARA). This enables the earliest available risk assessment for the development of autism in a child, even before clinical symptoms exist. The company's mission is to detect, and ultimately ensure from occurring the MARA subtype that has been shown to be associated with more severe forms of autism. For more information, please visit SOURCE MARAbio

LineaGen Research Frequently Asked Questions (FAQ)

  • When was LineaGen Research founded?

    LineaGen Research was founded in 2002.

  • Where is LineaGen Research's headquarters?

    LineaGen Research's headquarters is located at 2677 E Parleys Way, Salt Lake City.

  • What is LineaGen Research's latest funding round?

    LineaGen Research's latest funding round is Acquired.

  • How much did LineaGen Research raise?

    LineaGen Research raised a total of $60.37M.

  • Who are the investors of LineaGen Research?

    Investors of LineaGen Research include BioNano Genomics, Mesa Verde Venture Partners, Sanderling Ventures, PrairieGold Venture Partners, Signal Peak Ventures and 14 more.

  • Who are LineaGen Research's competitors?

    Competitors of LineaGen Research include Brain Tunnelgenix Technologies, STARR Life Sciences, Integrated Diagnostics, Advanced Cell Diagnostics, Magellan Biosciences and 7 more.


Compare LineaGen Research to Competitors

hanse chemie GmbH

Micronics, Inc. is a developer of near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. The Company employs a core patent estate in microfluidics -- the ability to miniaturize complex tests onto credit card size disposable devices. Per the company, tests that today take hours to days in a central laboratory environment are processed on a Micronics disposable device in seconds to minutes.


NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.

Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.


Glycominds Ltd. holds knowledge and experience in the field of glycomics, utilized for the discovery and development of glycan biomarkers which enable high-value medical diagnostics. Glycominds is developing and commercializing a new class of blood tests which allow physicians to detect cancer earlier, predict autoimmune disease progression and decide on therapy regimen.


ViralTest offers molecular-based diagnostics development for niche infectious diseases markets.


theraGenetics is a personalized medicine diagnostics company developing pharmacogenetic tests to guide and improve the treatment of central nervous system (CNS) disorders; matching the medication to the patient.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.